L&K Biomed's U.S. subsidiary, L&K Spine, announced on the 7th that it has achieved 3,000 surgeries using PathLoc-TM in the United States.
Becker's Spine, a U.S. spine specialty publication, reported that after starting the first surgery in April 2022, 1,000 surgeries were reached in December 2023, and 2,000 surgeries in July 2024. It took 1 year and 8 months to reach 1,000 surgeries after the first operation, and then an additional 1,000 surgeries were performed within a year. L&K Spine is solidifying its position in the U.S. market for height-expandable cage products. Among the 3,000 PathLoc-TM devices used in the U.S., there have been no cases of malfunctions or postoperative complications caused by the product, proving its safety and excellence.
PathLoc-TM is the most frequently used posterior and posterolateral insertion product. The core competitiveness of height-expandable products lies in how accurately the implant height can be ergonomically adjusted. Depending on the patient's spinal environment, the insertion angle (up to 20 degrees) and length (up to 25 mm) can be selected, and the height can be increased (up to 4 mm). This design makes it a highly competitive product in the global market.
An L&K Biomed official stated, "Surpassing 3,000 surgeries using PathLoc-TM proves that our spinal implant products have firmly established their position in the U.S. market," and added, "The growth trend is accelerating."
They also said, "The FDA-approved ‘BlueX Series’ is expected to further accelerate sales in the U.S. market alongside PathLoc-TM," and added, "With enhanced product competitiveness, we will conduct aggressive marketing to expand market share and increase brand awareness in the U.S."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
